EVABAVE Trademark

Trademark Overview


On Monday, September 11, 2017, a trademark application was filed for EVABAVE with the United States Patent and Trademark Office. The USPTO has given the EVABAVE trademark a serial number of 87603589. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 2, 2021. This trademark is owned by Eli Lilly and Company. The EVABAVE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
evabave

General Information


Serial Number87603589
Word MarkEVABAVE
Filing DateMonday, September 11, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 2, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 1, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 15, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, August 2, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 2, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, December 8, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 7, 2020EXTENSION 5 GRANTED
Tuesday, November 17, 2020EXTENSION 5 FILED
Tuesday, November 17, 2020TEAS EXTENSION RECEIVED
Friday, May 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 20, 2020EXTENSION 4 GRANTED
Wednesday, May 20, 2020EXTENSION 4 FILED
Wednesday, May 20, 2020TEAS EXTENSION RECEIVED
Tuesday, November 26, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 22, 2019EXTENSION 3 GRANTED
Friday, November 22, 2019EXTENSION 3 FILED
Friday, November 22, 2019TEAS EXTENSION RECEIVED
Friday, June 7, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 5, 2019EXTENSION 2 GRANTED
Wednesday, June 5, 2019EXTENSION 2 FILED
Wednesday, June 5, 2019TEAS EXTENSION RECEIVED
Friday, November 30, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 29, 2018EXTENSION 1 GRANTED
Monday, November 19, 2018EXTENSION 1 FILED
Thursday, November 29, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, November 19, 2018TEAS EXTENSION RECEIVED
Tuesday, June 26, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 1, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 1, 2018PUBLISHED FOR OPPOSITION
Wednesday, April 11, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 23, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 23, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 23, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, March 18, 2018ASSIGNED TO LIE
Tuesday, March 6, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, September 30, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, September 30, 2017NON-FINAL ACTION E-MAILED
Saturday, September 30, 2017NON-FINAL ACTION WRITTEN
Saturday, September 30, 2017ASSIGNED TO EXAMINER
Friday, September 15, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, September 14, 2017NEW APPLICATION ENTERED IN TRAM